BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
NCT07923019, Not applicable, Not yet recruiting, Singapore National Eye Centre
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment | ClinicalTrials.gov |
| NCT number | NCT07923019 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Singapore National Eye Centre | ClinicalTrials.gov |
| Conditions | Myopia, Myopia Progressing, Myopia Progression, Light | ClinicalTrials.gov |
| Interventions | Repeated low-level red-light (RLRL) therapy, Continued existing myopia treatment strategy | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Best-Corrected Visual Acuity | Baseline to 12 months, with assessments at 1, 3, 6 and 12 months. | Change in best-corrected distance and near visual acuity, measured in logMAR units, to assess visual safety during treatment. A decrease of at least one line in best-corrected visual acuity meets the protocol-defined withdrawal criterion. | ClinicalTrials.gov |
| Primary | Occurrence of Retinal Structural Abnormalities | Throughout the 12-month study period. | Number and proportion of participants developing retinal structural abnormalities during follow-up. Retinal safety assessments include optical coherence tomography of the macula, fundus photography, fundus autofluorescence and optical coherence tomography angiography. | ClinicalTrials.gov |
| Primary | Occurrence of Retinal Functional Abnormalities | Throughout the 12-month study period. | Number and proportion of participants developing retinal functional abnormalities during follow-up. Assessments include colour vision, Amsler grid testing, contrast sensitivity, dark-adapted testing, microperimetry and multifocal electroretinography to detect potential retinal toxicity. | ClinicalTrials.gov |
| Secondary | Proportion of Participants Achieving Effective Myopia Control | At 12 months. | Proportion of participants achieving effective myopia control after 12 months of RLRL therapy, assessed using axial elongation and spherical equivalent refractive progression. | ClinicalTrials.gov |
| Secondary | Change in Axial Length | Baseline to 12 months, with measurements at 1, 3, 6 and 12 months. | Change in axial length, measured in millimetres, from baseline. Longitudinal changes will be evaluated using mixed-model analyses. | ClinicalTrials.gov |
| Secondary | Change in Spherical Equivalent Refraction | Baseline to 12 months, with measurements at 6 and 12 months. | Change in cycloplegic spherical equivalent refraction, measured in dioptres, from baseline. Longitudinal changes will be evaluated using mixed-model analyses. | ClinicalTrials.gov |
| Secondary | Change in Choroidal Thickness | Baseline to 12 months, with measurements at 1, 3, 6 and 12 months. | Change in choroidal thickness, measured using optical coherence tomography, from baseline to assess the anatomical response to treatment. | ClinicalTrials.gov |
| Secondary | Change in Retinal Function | - Through 12 months, according to the protocol-specified assessment schedule. | Changes in retinal function assessed using contrast sensitivity, dark-adapted testing, microperimetry and multifocal electroretinography. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)